Complete financial analysis of Navidea Biopharmaceuticals, Inc. (NAVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Navidea Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wildpack Beverage Inc. (CANS.V) Income Statement Analysis – Financial Results
- Tsaker New Energy Tech Co., Limited (1986.HK) Income Statement Analysis – Financial Results
- Health Assurance Acquisition Corp. (HAAC) Income Statement Analysis – Financial Results
- Cover Technologies Inc. (MGPRF) Income Statement Analysis – Financial Results
- Hunan Tyen Machinery Co.,Ltd (600698.SS) Income Statement Analysis – Financial Results
Navidea Biopharmaceuticals, Inc. (NAVB)
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.65K | 531.51K | 915.01K | 26.62K | 322.52K | 1.81M | 21.97M | 13.25M | 6.27M | 1.13M | 78.74K | 597.73K | 10.70M | 9.52M | 7.89M | 7.12M | 6.05M | 5.92M | 5.95M | 6.51M | 4.92M | 7.58M | 9.71M | 9.45M | 5.83M | 5.13M | 1.17M | 1.00M | 900.00K | 100.00K | 100.00K |
| Cost of Revenue | 184.95K | 198.83K | 1.05K | 6.67K | 96.64K | 3.65K | 2.30M | 1.75M | 1.59M | 332.82K | 0.00 | 0.00 | 3.21M | 3.13M | 3.01M | 3.18M | 2.63M | 2.38M | 2.34M | 3.12M | 2.35M | 4.39M | 4.63M | 3.95M | 1.40M | 1.58M | 676.77K | 500.00K | 100.00K | 5.90M | 100.00K |
| Gross Profit | -119.30K | 332.68K | 913.97K | 19.95K | 225.89K | 1.81M | 19.67M | 11.49M | 4.69M | 797.82K | 78.74K | 597.73K | 7.49M | 6.38M | 4.88M | 3.94M | 3.42M | 3.54M | 3.61M | 3.38M | 2.57M | 3.20M | 5.08M | 5.49M | 4.43M | 3.55M | 494.41K | 500.00K | 800.00K | -5.80M | 0.00 |
| Gross Profit Ratio | -181.71% | 62.59% | 99.89% | 74.95% | 70.04% | 99.80% | 89.54% | 86.76% | 74.72% | 70.56% | 100.00% | 100.00% | 70.03% | 67.07% | 61.83% | 55.30% | 56.50% | 59.86% | 60.61% | 52.00% | 52.22% | 42.17% | 52.31% | 58.13% | 75.93% | 69.27% | 42.21% | 50.00% | 88.89% | -5,800.00% | 0.00% |
| Research & Development | 5.97M | 5.14M | 4.93M | 5.34M | 4.22M | 4.51M | 8.88M | 12.79M | 16.78M | 23.71M | 16.89M | 15.15M | 9.22M | 4.97M | 4.51M | 2.87M | 3.80M | 4.03M | 2.45M | 1.89M | 2.32M | 344.68K | 472.73K | 1.31M | 12.96M | 19.66M | 16.08M | 7.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 7.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.96M | 7.45M | 6.69M | 6.28M | 7.70M | 11.17M | 13.01M | 17.26M | 15.54M | 15.53M | 11.18M | 9.55M | 4.58M | 3.24M | 3.41M | 2.84M | 3.08M | 3.16M | 3.15M | 3.10M | 3.27M | 2.32M | 2.96M | 8.21M | 10.55M | 11.16M | 7.75M | 3.60M | 12.00M | 2.30M | 2.90M |
| Other Expenses | 0.00 | -14.12K | -21.86K | -631.21K | 1.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 552.96K | 9.38M | 0.00 | 0.00 | 500.00K | 600.00K | 100.00K | 100.00K |
| Operating Expenses | 13.93M | 12.59M | 11.63M | 10.98M | 11.07M | 15.68M | 21.90M | 30.05M | 32.32M | 39.24M | 28.07M | 24.70M | 13.80M | 8.21M | 7.92M | 41.23M | 6.88M | 7.19M | 5.61M | 5.00M | 5.59M | 2.67M | 3.43M | 10.07M | 32.90M | 30.82M | 23.84M | 11.90M | 12.60M | 2.40M | 3.00M |
| Cost & Expenses | 14.12M | 12.59M | 11.63M | 10.99M | 11.17M | 15.69M | 24.19M | 31.80M | 33.91M | 39.57M | 28.07M | 24.70M | 17.01M | 11.34M | 10.93M | 44.42M | 9.51M | 9.56M | 7.95M | 8.12M | 7.94M | 7.05M | 8.06M | 14.03M | 34.30M | 32.39M | 24.51M | 12.40M | 12.70M | 8.30M | 3.10M |
| Interest Income | 0.00 | 6.00K | 11.34K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 | 16.10K | 18.84K | 25.04K | 25.76K | 8.80K | 18.75K | 60.86K | 70.98K | 225.47K | 226.66K | 28.87K | 9.42K | 74.26K | 127.66K | 205.96K | 0.00 | 598.83K | 0.00 | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.10M | 6.36K | 0.00 | 25.29K | 30.80K | 168.97K | 4.87K | 1.27M | 3.71M | 2.78M | 1.17M | 13.33K | 554.99K | 1.53M | 1.74M | 2.28M | 1.50M | 1.35M | 334.20K | 186.91K | 31.95K | 11.10K | 24.88K | 0.00 | 189.79K | 0.00 | 83.44K | 200.00K | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 95.82K | 198.83K | 190.58K | 144.51K | 150.39K | 254.59K | 501.37K | 571.42K | 500.18K | 404.18K | 200.22K | 176.54K | 223.46K | 333.75K | 408.35K | 1.81M | 1.22M | 1.29M | 856.01K | 757.78K | 796.83K | 423.12K | 392.50K | 552.96K | 1.12M | 896.52K | 652.62K | -500.00K | -600.00K | -100.00K | -100.00K |
| EBITDA | -13.88M | -11.51M | -10.64M | -10.82M | -10.85M | -13.14M | -6.87M | -21.31M | -31.52M | -38.03M | -27.79M | -24.86M | -49.10M | -35.85M | -2.48M | -2.40M | -2.83M | -2.97M | -1.14M | -853.34K | -2.22M | 955.59K | 1.67M | -4.03M | -27.20M | -26.37M | -22.97M | -11.80M | -12.10M | -8.40M | -3.10M |
| EBITDA Ratio | -21,134.32% | -2,337.93% | -1,170.60% | -41,184.60% | -1,722.58% | -541.05% | -20.54% | -114.85% | -448.72% | -3,399.73% | -35,547.39% | -3,998.82% | 345.15% | 341.96% | -27.82% | -482.39% | -36.85% | -37.03% | 1.57% | -12.95% | -45.50% | 20.93% | 17.16% | -46.74% | -469.25% | -551.70% | -1,960.93% | -1,180.00% | -1,344.44% | -8,400.00% | -3,100.00% |
| Operating Income | -14.05M | -12.06M | -10.71M | -10.96M | -10.85M | -13.88M | -2.22M | -18.55M | -27.63M | -38.44M | -27.99M | -24.10M | -6.31M | -1.82M | -3.04M | -1.76M | -3.46M | -3.64M | -2.00M | -1.61M | -2.99M | -352.21K | 1.29M | -4.58M | -28.47M | -27.26M | -23.34M | -11.40M | -11.80M | -8.20M | -3.00M |
| Operating Income Ratio | -21,402.08% | -2,269.07% | -1,170.60% | -41,184.60% | -3,363.29% | -766.50% | -10.12% | -140.01% | -440.38% | -3,399.73% | -35,547.39% | -4,032.67% | -58.98% | -19.17% | -38.57% | -24.74% | -57.19% | -61.56% | -33.58% | -24.75% | -60.82% | -4.64% | 13.25% | -48.50% | -488.08% | -531.69% | -1,993.02% | -1,140.00% | -1,311.11% | -8,200.00% | -3,000.00% |
| Total Other Income/Expenses | -1.13M | 345.52K | -10.51K | 17.68K | -5.32M | -3.91M | 2.77M | -10.32M | -13.14M | -4.26M | -1.17M | -943.16K | -37.20M | 1.82M | -2.12M | -3.33M | -1.28M | -1.28M | -1.24M | -10.38K | 28.48K | 369.77K | 371.83K | 386.58K | 26.50K | 1.92M | 276.87K | 900.00K | 900.00K | 300.00K | 200.00K |
| Income Before Tax | -15.18M | -11.71M | -10.72M | -10.94M | -16.17M | -17.79M | -14.31M | -28.76M | -35.73M | -42.70M | -29.16M | -25.05M | -49.96B | -39.61B | -5.17B | -5.09B | -4.74B | -4.93B | -3.24M | -1.62M | -2.96M | 17.57K | 1.66M | -4.19M | -28.44M | -25.34M | -23.07M | -10.50M | -10.90M | -7.90M | -2.80M |
| Income Before Tax Ratio | -23,117.58% | -2,204.06% | -1,171.75% | -41,118.20% | -5,013.18% | -982.62% | -65.13% | -217.05% | -569.36% | -3,776.61% | -37,030.66% | -4,190.46% | -466,936.68% | -416,112.49% | -65,509.12% | -71,415.40% | -78,353.34% | -83,266.70% | -54.36% | -24.91% | -60.24% | 0.23% | 17.08% | -44.41% | -487.63% | -494.19% | -1,969.38% | -1,050.00% | -1,211.11% | -7,900.00% | -2,800.00% |
| Income Tax Expense | 0.00 | 16.04K | -81.74K | 707.00 | 2.75K | -4.06M | -648.00K | -436.05K | 2.68M | 2.37M | 43.33M | -7.88M | 43.65M | 37.45M | 2.12M | -32.20M | 1.28M | 1.28M | 1.54M | 187.87K | -726.00 | 2.62K | -194.07K | -407.40K | -435.54K | -4.02M | -2.37M | 400.00K | 200.00K | 0.00 | -200.00K |
| Net Income | -15.18M | -11.73M | -10.64M | -10.95M | -16.13M | 74.95M | -14.31M | -27.56M | -35.73M | -42.70M | -29.16M | 5.61M | -49.96M | -39.61M | -5.17M | -5.09M | -4.74M | -4.93M | -3.54M | -1.80M | -2.96M | 14.95K | 1.84M | -4.17M | -28.03M | -23.25M | -20.97M | -10.80M | -10.80M | -8.00M | -2.60M |
| Net Income Ratio | -23,117.58% | -2,207.08% | -1,162.82% | -41,120.85% | -5,000.12% | 4,139.67% | -65.13% | -208.03% | -569.36% | -3,776.61% | -37,030.66% | 939.05% | -466.94% | -416.11% | -65.51% | -71.42% | -78.35% | -83.27% | -59.49% | -27.63% | -60.23% | 0.20% | 18.95% | -44.19% | -480.61% | -453.33% | -1,790.42% | -1,080.00% | -1,200.00% | -8,000.00% | -2,600.00% |
| EPS | -0.59 | -0.40 | -0.45 | -0.76 | -1.89 | 9.40 | -1.84 | -3.65 | -4.80 | -7.01 | -5.89 | 1.20 | -12.38 | -10.74 | -1.51 | -1.62 | -1.62 | -1.69 | -1.25 | -0.89 | -1.64 | 0.01 | 0.80 | -3.63 | -24.54 | -20.45 | -21.17 | -15.55 | -23.60 | -22.60 | -8.20 |
| EPS Diluted | -0.56 | -0.40 | -0.45 | -0.76 | -1.89 | 9.00 | -1.84 | -3.65 | -4.80 | -7.01 | -5.89 | 1.20 | -12.38 | -10.74 | -1.51 | -1.62 | -1.62 | -1.69 | -1.25 | -0.89 | -1.64 | 0.01 | 0.80 | -3.63 | -24.54 | -20.31 | -21.17 | -15.55 | -23.60 | -22.60 | -8.20 |
| Weighted Avg Shares Out | 29.34M | 29.34M | 23.90M | 14.39M | 8.53M | 8.08M | 7.77M | 7.56M | 7.44M | 6.09M | 4.95M | 4.53M | 4.04M | 3.69M | 3.43M | 3.15M | 2.93M | 2.92M | 2.84M | 2.02M | 1.80M | 1.29M | 1.29M | 1.15M | 1.14M | 1.14M | 990.57K | 694.44K | 457.63K | 353.98K | 317.07K |
| Weighted Avg Shares Out (Dil) | 30.90M | 29.34M | 23.90M | 14.39M | 8.53M | 8.30M | 7.77M | 7.56M | 7.44M | 6.09M | 4.95M | 4.53M | 4.04M | 3.69M | 3.43M | 3.15M | 2.93M | 2.92M | 2.84M | 2.02M | 1.80M | 1.30M | 1.32M | 1.15M | 1.14M | 1.14M | 990.57K | 694.44K | 457.63K | 353.98K | 317.07K |
Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced preliminary results from the ongoing NAV3-32 Phase 2B study titled, “A Comparison of Tc99m...
Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced preliminary results from the ongoing NAV3-32 Phase 2B study titled, “A Comparison of Tc99m...
Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the results of an updated third-party asset valuation of its Rheumatoid Arthritis (“RA”) diagnostic...
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has received a Notice of Allowance for the patent application titled, “Compounds...
Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the regulatory approval of Lymphoaim (“Lymphoseek” in the rest of the world; Tc99m tilmanocept)...
Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has adopted a Section 382 Rights Agreement that is...
Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has adopted a Section 382 Rights Agreement that is...
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
DUBLIN, Ohio--(BUSINESS WIRE)--As previously disclosed, on January 28, 2022, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received a notification from the NYSE American stating that...
Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today welcomed Kenneth Berger, Ph.D., as Senior Regulatory Consultant, and the return of the Company's former...
Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2021 Results - Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports